INTEGRA LIFESCIENCES HOLDINGS CORP 10-Q

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS The following table provides information about purchases by us during the quarter ended March 31, 2023 of equity securities that are registered by us pursuant to Section 12 of the Exchange Act. Subject to applicable law, share repurchases may be made from time to time in open market transactions, privately negotiated transactions including accelerated share repurchase agreements, or pursuant to instruments and plans complying with Rule 10b5-1 under the Exchange Act, among other types of transactions and arrangements. Issuer purchases of equity securities Period Total number of shares purchased by month Average price paid per share Total number of shares purchased by month as part of publicly announced repurchase programs Approximate dollar value of shares that may yet be purchased under the plans or program 01/01/23 - 01/31/23 2,111,189 $ 56.68 2,111,189 30,000,000 02/01/23 - 02/28/23 — — — — 03/01/23 - 03/31/23 — — — — 2,111,189 $ 56.68 2,111,189 30,000,000 On January 26, 2023, the Company entered into the 2023 ASR and received 2.1 million shares of our common stock at inception of the 2023 ASR, which represented approximately 80% of the expected total shares under the 2023 ASR. The remaining repurchase transactions are expected to be completed in the second quarter of 2023. See Note 11, Treasury Stock, to the Notes to Consolidated Financial Statements (Part I, Item 1 of this Quarterly Report) for additional information regarding our share repurchase program and the 2023 ASR. ITEM 4. MINE SAFETY DISCLOSURES Not applicable.